Bifogade filer
2022-01-18-Xintela-granted-48-MSEK.pdf
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Lund, Sweden, January 18, 2022 - Xintela has been granted SEK 4.8 million from Vinnova within the call "New and improved biological drugs in healthcare". The grant will support a clinical phase I/IIa study to evaluate Xintela's stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers.
The project, which will be partly financed by Vinnova, aims to evaluate the safety and efficacy of Xintela's stem cell product XSTEM in a clinical phase I/IIa study for treatment of difficult-to-heal venous leg ulcers, a painful disease that affects about 4% of the population over 65 years. The clinical study will be performed in collaboration with Professor Folke Sjöberg and his team at the Burn Center at Linköping University Hospital.
Xintela's application received the maximum grant, where 9 applications were granted a total of SEK 45 million in funding.
-It is very gratifying that Vinnova has approved our application, which shows that our project is of high quality and competitive. The medical need in patients with difficult-to-heal venous leg ulcers is huge and entails significant costs for healthcare. The financial support from Vinnova helps us to develop XSTEM into a new and effective treatment for this large patient group, says Xintela's CEO Evy Lundgren-Åkerlund.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
This information is such information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 p.m CET on January 18, 2022.
The following documents can be retrieved from beQuoted
2022-01-18-Xintela-granted-48-MSEK.pdf
About Xintela
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin a10b1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.